Estradiol-6 [BSA] (DAG2985)

Product Overview
Estradiol, BSA-Conjugated
Target
Estradiol
Nature
Synthetic
Tag/Conjugate
BSA
Procedure
None
Format
Liquid
Concentration
2.0 mg/mL
Size
1 mg
Buffer
Supplied in 0.015 M phosphate, 0.15 M NaCl, pH 7.2
Preservative
0.1% Sodium Azide
Storage
2-8°C short term, -20°C long term
Warnings
PLEASE note that this product is intended for research use only; not for diagnostic or clinical use.
Introduction
17 beta Estradiol is a steriod hormone that is produced in the ovary, placenta, testis, and possibly the adrenal cortex.
Keywords
17 beta Oestradiol; estradiol

Citations


Have you cited DAG2985 in a publication? Let us know and earn a reward for your research.

Related Products


Estradiol [AP] (DAG2986)
Estradiol [BSA] (DAGA-025B)
Estradiol [KLH] (DAGA-028K)
Estradiol [HRP] (DAGA-025B-HRP)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Buckwheat, rooibos, and vitex extracts can mitigate adverse effects of xylene on ovarian cells in vitro

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

Authors: Sirotkin, Alexander V.; Macejkova, Martina; Tarko, Adam; Fabova, Zuzana; Alwasel, Saleh; Harrath, Abdel Halim

This study examines whether selected functional food and medicinal plants can mitigate the adverse effects of xylene on ovarian cells. The influences of xylene (0, 10, 100, or 1000 ng/mL), buckwheat (Fagopyrum esculentum), rooibos (Aspalathus linearis), vitex (Vitex agnus-castus), extracts (10 mu g/mL each), and a combination of xylene with these plant additives on cultured porcine ovarian granulosa cells are compared. Cell viability, proliferation (PCNA accumulation), apoptosis (accumulation of bax), and release of progesterone (P4) and estradiol (E2) were analyzed by the trypan blue tests, quantitative immunocytochemistry, and enzyme-linked immunosorbent assays, respectively. Xylene suppressed all measures of ovarian cell function. Rooibos prevented all of xylene's effects, whereas buckwheat and vitex prevented four of five of the analyzed effects (buckwheat prevented xylene influence on viability, PCNA, bax, and E2; vitex prevented xylene action on viability, PCNA, and P4 and E2). These observations show that xylene has the potential to suppress ovarian cell functions, and that buckwheat, rooibos, and vitex can mitigate those effects, making them natural protectors against the adverse effects of xylene on ovarian cells.

Comparison of Clinical Effectiveness of Deslorelin Acetate and Osaterone Acetate in Dogs with Benign Prostatic Hyperplasia

ANIMALS

Authors: Nizanski, Wojciech; Ochota, Malgorzata; Fontaine, Christelle; Pasikowska, Joanna

Simple Summary The article compares the treatment efficacy and adverse effects of two drugs used for benign prostate hyperplasia (BPH) therapy in dogs: Ypozane (osaterone acetate) and Suprelorin (deslorelin acetate). Ypozane is a registered medication for this condition in dogs, whereas Suprelorin is registered for pharmacological castration in dogs. The clinical trial proved both drugs to be safe and effective in reducing BPH-related symptoms in dogs, and the noted adverse effects were only mild-mostly weight gain. With osaterone acetate the clinical improvement was noted sooner (from day 7 onwards) than with Suprelorin (from day 21 onwards), but it lasted shorter up to 24 weeks, while in the Suprelorin group, clinical effect remained stable until the end of the study (36 weeks). Both medications can be recommended for treatment of symptoms related to BPH in dogs, as none of the drugs had serious influence on the general health status and both provided substantial clinical improvement. This article presents the results of a randomized clinical trial, designed to compare the efficacy and therapeutic profiles of Ypozane (osaterone acetate-OA) or Suprelorin (deslorelin acetate-DA) in male dogs with clinical signs of benign prostate hyperplasia (BPH). Forty-five intact male dogs were used in the study. The Group I (negative control) included 10 healthy dogs, the Group II (positive control) included 10 dogs with confirmed BPH and no treatment, whereas Group III and IV consisted of dogs with BPH and treated either with DA (15 dogs) or OA (10 dogs). The clinical response, testosterone and estradiol levels, hematology, biochemistry, and adverse effects incidence were evaluated. Both OA and DA proved to be effective for BPH treatment in dogs, as they allowed for the clinical remission in all treated dogs. The complete alleviation of BPH symptoms was noticed sooner with the use of OA (in 80% of dogs from day 7) compared to DA (in 40% of dogs within the first 21 days). The recurrence of clinical signs related to BPH was observed from week 24 in dogs treated with OA, whereas no relapse was noticed in dogs treated with DA at the end of the 36 weeks of the observation period. In 5 dogs (33%) treated with DA, a flare-up effect (increase in the clinical signs associated with BPH) was noticed on day 7. Despite individual differences in the clinical action, both medications were effective and safe options for the treatment of symptoms related to BPH in dogs.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket